Disclosed herein are non-naturally existing novel platelet variants or platelet like cells (PLCs), extracellular vesicles (EVs), and derivatives thereof. Composition comprising the same and methods for treatment or prevention of diseases or disorders therewith is also disclosed.

Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment fibroblasts are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment fibroblasts are cultured with platelet rich plasma and/or derivatives from platelet rich plasma. In another embodiment, fibroblasts are cultured under hypoxic conditions prior to administration to an individual. The disclosure further provides means of assessment of fibroblast activity in vitro, including wound repair assay and cytokine production, for example.

The present invention discloses a composition comprising extracellular vesicles (EVs) of placenta tissue derived CD106.sup.high CD151.sup.+Nestin.sup.+ mesenchymal stem cells (MSCs). In a first aspect, the invention relates to a particular method to prepare these EVs. In a second aspect, the invention relates to a therapeutic, a diagnostic, a veterinary or a cosmetic composition comprising the extracellular vesicles (EVs) obtained by said particular method. In a third aspect, the invention relates to a composition comprising these EVs, for use as a medicament for treating subjects suffering from an ischemic disease, a disorder of the circulatory system, an immune disease, an organ injury or an organ function failure.

The present disclosure relates to a method for obtaining an antibody or antigen-binding fragment thereof that specifically binds to and against a tumor sample, comprising: administering autologous dendritic cells to a subject; taking immune cells and a tumor sample from the subject; constructing an antibody library of the immune cells; and screening the antibody library to obtain the antibody or a fragment thereof specifically binding to and against the tumor sample. The disclosure also relates to a method for engineering immune cells, an antibody or antigen-binding fragment thereof that specifically binds to and against a tumor sample and uses thereof.

The invention relates to progenitor cells of mesodermal lineage and their use in therapy.

The present invention relates to production of therapeutic potential WJ-MSCs for clinical purposes. The WJ-MSCs cultured in optimal culture conditions for production of clinical grade WJ-MSCs wherein 4 different culture media which are Media A, Media B, Media C and Media D used to produce 4 types of WJ-MSCs with different therapeutic potential. The WJ-MSCs harvested from Media A has therapeutic potential related to immune, wound healing and cell migration and the WJ-MSCs harvested from Media B has therapeutic potential related to localization, cell proliferation and cell migration. Meanwhile, the WJ-MSCs harvested from Media C has therapeutic potential related to organ development and osteogenesis and the WJ-MSCs harvested from Media D has therapeutic potential related to tissue development, cell signaling and localization.

An object of the present invention is to provide a cell population comprising safe adherent stem cells maintaining a normal karyotype and a method for producing the cell population, and a pharmaceutical composition comprising the cell population. According to the present invention, a production method of a cell population comprising adherent stem cells, comprising obtaining a cell population in which the proportion of KCNAB1-positive adherent stem cells in the cell population is 85% or more, is provided.

An object of the present invention is to provide a cell population comprising adherent stem cells and exhibiting high immunosuppressive activity and/or proliferative property and a production method of the cell population, and a pharmaceutical composition comprising the cell population. The present invention provides a production method of a cell population comprising adherent stem cells, the method comprising obtaining a cell population having the following cell characteristics (a) and (b): (a) the cell population is positive for expressions of PLIN2 gene and NEFM gene, (b) the cell population satisfies the relative expression level of PLIN2 gene to the expression level of SDHA gene of 1.50 or more.

The invention relates to progenitor cells of mesodermal lineage and their use in therapy.

A method for expanding circulating tumor cell in vitro includes preparing a cell culture tool having a multi-particle colloidal crystal layer, preparing a cell solution including circulating tumor cells, and contacting the cell solution with the multi-particle colloidal crystal layer, to attach the circulating tumor cells in the cell solution to the multi-particle colloidal crystal layer and rapidly expand by 20 times or more. The multi-particle colloidal crystal layer at least includes first particles having a particle size of 1000 to 5000 nm and second particles having a particle size of 20 to 400 nm. The culture medium in the cell solution at least includes a platelet lysate.